Sphingosine‐1‐Phosphate is Involved in the Occlusive Arteriopathy of Pulmonary Arterial Hypertension

Pulmonary Circulation - Tập 6 Số 3 - Trang 369-380 - 2016
Salina Gairhe1,2, Sachindra R. Joshi1,3, Mrigendra M. Bastola1, Jared M. McLendon1,3, Masahiko Oka1,2, Karen A. Fagan1,2, Ivan F. McMurtry1,2
1Center for Lung Biology, College of Medicine, University of South Alabama, Mobile, Alabama, USA
2Departments of Internal Medicine and Pharmacology, College of Medicine, University of South Alabama, Mobile, Alabama, USA
3Department of Biochemistry, College of Medicine, University of South Alabama, Mobile, Alabama, USA

Tóm tắt

Despite several advances in the pathobiology of pulmonary arterial hypertension (PAH), its pathogenesis is not completely understood. Current therapy improves symptoms but has disappointing effects on survival. Sphingosine‐1‐phosphate (S1P) is a lysophospholipid synthesized by sphingosine kinase 1 (SphK1) and SphK2. Considering the regulatory roles of S1P in several tissues leading to vasoconstriction, inflammation, proliferation, and fibrosis, we investigated whether S1P plays a role in the pathogenesis of PAH. To test this hypothesis, we used plasma samples and lung tissue from patients with idiopathic PAH (IPAH) and the Sugen5416/hypoxia/normoxia rat model of occlusive PAH. Our study revealed an increase in the plasma concentration of S1P in patients with IPAH and in early and late stages of PAH in rats. We observed increased expression of both SphK1 and SphK2 in the remodeled pulmonary arteries of patients with IPAH and PAH rats. Exogenous S1P stimulated the proliferation of cultured rat pulmonary arterial endothelial and smooth‐muscle cells. We also found that 3 weeks of treatment of late‐stage PAH rats with an SphK1 inhibitor reduced the increased plasma levels of S1P and the occlusive pulmonary arteriopathy. Although inhibition of SphK1 improved cardiac index and the total pulmonary artery resistance index, it did not reduce right ventricular systolic pressure or right ventricular hypertrophy. Our study supports that S1P is involved in the pathogenesis of occlusive arteriopathy in PAH and provides further evidence that S1P signaling may be a novel therapeutic target.

Từ khóa


Tài liệu tham khảo

10.1016/j.ahj.2007.02.037

10.1111/j.1365-2559.2012.04246.x

10.1164/rccm.201201-0164OC

10.1096/fj.05-4331fje

10.1016/j.semcdb.2004.05.002

10.1194/jlr.R800065-JLR200

10.4161/cbt.11.2.14624

10.2174/187152012800228643

10.1007/978-3-7091-1511-4_19

10.1164/rccm.201401-0121OC

10.1038/nrm1103

10.1100/tsw.2006.182

10.1016/j.pharmthera.2007.04.006

10.1152/ajplung.00233.2009

10.4103/2045-8932.87309

10.1016/j.jaci.2009.06.034

10.1126/scitranslmed.3006674

10.1161/CIRCULATIONAHA.109.927681

10.1096/fj.00-0343com

10.1152/ajpheart.00728.2013

10.1021/jm501760d

10.1042/BJ20110817

10.1152/ajplung.00183.2012

10.1161/01.RES.0000261658.12024.18

10.1016/j.jconrel.2015.05.261

10.1152/ajplung.1999.277.1.L119

10.1186/1465-9921-10-95

10.1038/nrc2875

10.1016/j.bbamcr.2011.11.016

10.1172/JCI76369

10.1016/S0002-8703(03)00118-2

10.1186/1465-9921-7-1

10.1371/journal.pone.0134958

10.1111/febs.12314

10.1172/JCI1910

10.1378/chest.114.3_Supplement.225S

10.1038/sj.bjc.6603400

10.1083/jcb.147.3.545

10.1158/0008-5472.CAN-11-2167

10.1111/j.1365-2184.2012.00807.x

10.1194/jlr.R800008-JLR200

10.2478/s11658-009-0009-1

10.1007/s10620-007-0133-6

10.1038/nrcardio.2011.87

10.1002/jcb.20088

10.1096/fj.05-3928com

10.1113/expphysiol.2014.082149

10.1152/ajpcell.00059.2016

10.1007/978-3-7091-1511-4_10

10.1165/rcmb.2012-0411TR

10.1073/pnas.1421190112

10.1152/ajpheart.00746.2012

10.1161/CIRCHEARTFAILURE.111.966127

10.1152/ajpheart.00372.2015

10.1164/rccm.201103-0412OC

10.1161/CIRCULATIONAHA.116.021494

Thông tin
Thông tin xuất bản

Pulmonary Circulation

Tập 6 Số 3

369-380

Thông tin tác giả